significant reduction in cancer mortality, but also of other distinct endpoints. It is desirable to evaluate derivative endpoints that can reliably predict reductions in mortality. The term "derivative" means a variable that is related to the true endpoint and is likely to be observable before the primary endpoint. Derivative endpoints may include thyroid cancer incidence, the proportion of early-stage tumors detected, more treatable stage, the identification of small tumors (to maintain in observation), decrease in the number of people who develop metastatic disease, the increased chance of lesser extent surgery, and the application of minimally invasive approaches, as well as no need for lifelong thyroid replacement therapy, a consistent follow-up, low-dose or no RAI administration and risk factor assessments where case findings should be continuous. The Korean guidelines for thyroid cancer national-level screening were published by a relevant group of multidisciplinary thyroid experts. It was concluded that the evidence is insufficient to balance the benefits and harms of thyroid cancer screening. However, the paper seems to raise the necessary investments in future research and demand a complete analysis for derivative endpoints, and offer screening participants with complete information necessary to make decisions that will provide them with the most value when a small thyroid cancer is screen-identified.
to serious academic discussions on the topic among medical epidemiologists and thyroid specialists [1] [2] [3] [4] [5] [6] [7] [8] .
It seems serious because quite a large number of patients who were diagnosed with thyroid cancer were reluctant to undergo proper therapeutic surgery in Korea [9] . Whereas more than 43,000 operations for thyroid cancer were performed from the second quarter of 2013 through the first quarter of 2014, approximately 28,000 operations were performed from the second quarter of 2014 through the first quarter of 2015, a 35% reduction [9] . Preliminary estimates from insurance claims suggest a 30% reduction in the incidence of thyroid cancer (the lag time in the availability of incidence data from the Korean Central Cancer Registry is 2-3 years) [9] . Thus, the decrease in the number of surgical operations was not primarily the result of more conservative surgical practice (e.g., opting for active surveillance instead); rather, it resulted from less screening and less diagnosis [9] .
Screening for thyroid cancer has not been recommended by any public organization or institution to date [3, 4, 10] . Based on the Korean reports on thyroid cancer screening, institutions may confirm similar advice [5] [6] [7] 10] .
From the thyroid specialist's point of view, we may recommend that the data offered should be interpreted with caution and that it is still premature to offer a definitive recommendation on thyroid cancer screening programs.
Theoretically, cancer screening is aimed primarily at reducing deaths from the specific cancer. Thyroid-specific cancer mortality may be the most demanding and ambitious endpoint for obtaining estimates of screening effect. Numerous observations have accumulated over the years, indicating that thyroid cancer mortality endpoint has been difficult to study and is confounded by population heterogeneity, provision of randomization, and requirement of large cohorts with sufficiently long follow-up due to the excellent prognosis of the cancer [6, 10] . The median survival time after diagnosis for thyroid cancer is quite long [6, 10] . Deaths from screening cancers will substantially lag behind the time of cancer detection. Accordingly, it may be important to reconsider how to best measure thyroid cancer screening efficacy. Recommendations against thyroid cancer screening should be based upon trials designed to evaluate its effectiveness not only in significant reduction in cancer mortality, but also of other distinct endpoints [6, 10] .
We suggest that it is desirable to evaluate derivative endpoints that can reliably predict reductions in mortality. Derivative endpoints may include the proportion of early-stage tumors detected, the increased chance of lesser extensive surgery, the application of minimally invasive approaches, and low-dose or no RAI administration [3-5, 12, 13] .
We suggest that it is desirable to evaluate derivative endpoints that can reliably predict reductions in mortality. The term "derivative" means a variable that is related to the true endpoint and is likely to be observable before the primary endpoint. Derivative endpoints may include thyroid cancer incidence, the proportion of early-stage tumors detected, more treatable stage, the identification of small tumors (to maintain in observation), decrease in the number of people who develop metastatic disease, the increased chance of lesser extent surgery, and the application of minimally invasive approaches, as well as no need for lifelong thyroid replacement therapy, a consistent follow-up, low-dose or no RAI administration and risk factor assessments where case findings should be continuous [10, 11] .
Statistics data depict thyroid cancer incidence that has markedly increased and is the most common type of cancer in the Republic of Korea [1, 2]. The incidence is 2.2 times higher than that in Western countries [3, 4, [12] [13] [14] . This is mostly related to the detection of early-stage papillary thyroid cancer (PTC), the most prevalent thyroid cancer comprising more than 90% of thyroid cancer through use of ultrasound and fine-needle aspiration [3, 4, [12] [13] [14] . To gain the full benefit of the "screen-detected tumors," it is essential that registries also record "non-screen-detected cases." Such problems occur in all screening contexts, including ductal carcinoma in situ in breast, microinvasive cervix, indolent prostate, and Dukes' A colorectal cancers. The detection of small screening-detected tumors represents a negative effect of screening if their diagnosis and treatment lead to anxiety and morbidity.
Examination of the stage distribution of screen-detected cancers can give useful information on the likelihood of a survival benefit. In the setting of screening, early-stage disease is more frequent with an 80% incidence of microcarcinoma [12] [13] [14] . Screening-detected tumors are smaller [12] [13] [14] . These results are yet to be confirmed in Western countries where the mean tumor size is 2.5 cm and only 20% of tumors are <1 cm without a screening program [12] [13] [14] . The 10-year survival among patients with earlystage thyroid cancer ranges from 90 to 100% [12] [13] [14] . In order to avoid the pitfalls associated with lead time bias, it is important to use a fixed follow-up time point (for example, more than 10 years after commencement) rather than a survival time from diagnosis. Thus, it is necessary to have information on the survival distribution up to the predefined projected survival time for each stage of cancer. Favorable survival associated with early-stage disease underscores the potential role of thyroid cancer early detection by effective screening in the Republic of Korea.
The migration toward screening programs prompts the chance of less radical surgery [10, 14] . Guidelines have recommended conservative treatment with organ preserving for PTC measuring <1 cm [10, 14] . Studies have confirmed that hemithyroidectomy is as effective as total thyroidectomy for patients with <1 cm PTC [10, 14] . The rationale for hemithyroidectomy includes eliminating the risk of bilateral laryngeal nerve injury, permanent hypocalcemia, preventing the need for lifelong thyroid replacement in 60-80% of patients [10, 14] . Patients may receive low-dose RAI [4] [5] [6] . Patients may receive more frequent minimally invasive approach for a screen-detected <1 cm PTC with reduced pain, faster recovery, and good aesthetic result [10, 14] . Nowadays, there is an effective intervention for patients identified through early detection, with evidence of early treatment leading to better outcomes than late treatment [10, 14, 15] .
The incidence of thyroid cancer, the rise in early-stage cancer detected, the conservative treatment applied, the noninvasive approach proposed, the optimized follow-up and research as to the best outcome measure within which to measure our screening programs will all be important to determine the best way forward [12, 16] .
It is hoped that the experience with the dynamic screening programs in the Republic of Korea will aid to determine what these different endpoints lead to and will allow to define objectives. The Korean guidelines for thyroid cancer national-level screening were published by a relevant group of multidisciplinary thyroid experts [12] . This ponderous Korean analysis is appropriate [12] . It was concluded that the evidence is insufficient to balance the benefits and harms of thyroid cancer screening. However, the paper seems to raise the necessary investments in future research and demand a complete analysis for derivative endpoints [12] . This interdisciplinary "endpoints committee" is needed to make these measurements and offer screening participants with complete, appropriate information necessary to make decisions that will provide them with the most value when a small thyroid cancer is screen-identified [12] .
